⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272846 | 0.98 | — | — | |
| SCHEMBL23913177 | 0.81 | HPGD (0.39) | — | |
| SCHEMBL19776822 | 0.78 | ALDH1A1 (0.36) | — | |
| SCHEMBL20349728 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL22959796 | 0.76 | SIGMAR1 (0.42) | — | |
| SCHEMBL24919281 | 0.75 | FAAH (0.40) | — | |
| SCHEMBL24918920 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL25884119 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL24918878 | 0.75 | MEN1 (0.42) | — | |
| SCHEMBL26364039 | 0.75 | SIGMAR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |